Advertisement

The Association Between Cannabinoids and Psychosis

  • Sai Krishna Tikka
  • Deepak Cyril D’SouzaEmail author
Chapter

Abstract

According to the exogenous cannabinoid hypothesis, exposure to cannabis and cannabinoid receptor (CB1R) agonists (henceforth referred to as “cannabinoids”) is associated with a number of psychosis outcomes. The high rates and earlier onset of cannabis use, the legalization of “medical” marijuana (cannabis) and recreational cannabis use in some states, the increasing availability and use of edible cannabinoid products and highly potent synthetic cannabinoids (e.g., Spice and K-2), the increasing potency of cannabis, and the high rates of emergency department visits related to cannabinoids warrant the need to understand the relationship between cannabinoids and psychosis.

The relationship(s) between cannabinoids and psychosis may be categorized according to the temporal proximity of the onset of psychosis to cannabinoid exposure and the duration and clinical significance of psychosis. Cannabinoids are associated with psychosis that manifests soon after exposure, typically lasts only for the duration of intoxication (hours) and that typically does not involve significant clinical intervention. Cannabinoids are also associated with psychosis that manifests soon after exposure but lasts beyond the period of intoxication and often requires clinical intervention. Finally, exposure to cannabinoids has been associated with an increased risk for chronic psychotic disorders (e.g., schizophrenia) that emerges years later and that requires clinical intervention. The link between cannabinoids and chronic psychotic disorder is greater with earlier age of exposure, cumulative dose of exposure, childhood abuse, and genetic vulnerability. However, cannabinoids are neither necessary nor sufficient to cause a chronic psychotic disorder. More likely, cannabinoids are a “component cause” interacting with other known (family history) and unknown factors to result in psychosis outcomes. Further research is necessary to fully understand the mechanisms underlying these relationships between cannabinoids and psychosis.

Keywords

Cannabis Psychosis Schizophrenia Intoxication Hallucinations 

References

  1. 1.
    Maurer D, Vogel V. Narcotics and narcotics addiction. Springfield: Charles C Thomas; 1962.Google Scholar
  2. 2.
    Dhunjibhoy J. A brief résumé of the types of insanity commonly met with in india, with a fully description of “indian hemp insanity” peculiar to the country. Br J Psychiatry. 1930;76(313):254–64.Google Scholar
  3. 3.
    Benjamin A. Assassins. In: Stanton ERAL, editor. Cultural sociology of the Middle East, Asia, and Africa: an encyclopedia. London: SAGE; 2012. p. 21–2.Google Scholar
  4. 4.
    Elgood C. A Medical History of Persia and the Eastern Caliphate: from the Earliest Times Until the Year A.D. 1932. Cambridge: Cambridge University Press; 1951.Google Scholar
  5. 5.
    Baron E. Comprehensive review of medicinal Marijuana, Cannabinoids, and Therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55(6):885–916.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Moreau J. Hashish and mental illness (1845). New York: Raven Press; 1973.Google Scholar
  7. 7.
    Abel E. Jacques Joseph Moreau (1804–1884). Am J Psychiatry. 2005;162:3.CrossRefGoogle Scholar
  8. 8.
    Anthony J, Lopez-Quintero C, Alshaarawy O. Cannabis epidemiology: a selective review. Curr Pharm Des. 2017;22(42):6340–52.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Leinweber J, Cheng H, Lopez-Quintero C, Anthony J. Newly incident cannabis use in the United States, 2002-2011: a regional and state level benchmark. Peer J. 2017;5:e3616.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Johnston L, O’Malley P, Miech R, Bachman J, Schulenberg J. Monitoring the Future National Survey on Drug Use 1975–2013. 2013 Overview: Key Findings on Adolescent Drug Use., University of Michigan, Institute for Social Research, Ann Arbor, MI, 2014.Google Scholar
  11. 11.
    Golub A, Johnson B, Dunlap E, Sifaneck S. Projecting and monitoring the life course of the Marijuana/Blunts generation. J Drug Issues. 2004;34(2):361–88.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ashton C. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178(1):101–6.CrossRefGoogle Scholar
  13. 13.
    ElSohly M, Gul W. Constituents of cannabis sativa. In: Pertwee R, editor. Handbook of Cannabis. London: Oxford University Press; 2014. p. 3–22.CrossRefGoogle Scholar
  14. 14.
    Agurell S, Halldin M, Lindgren J, Ohlsson A, Widman M, Gillespie H, Hollister L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38(1):21–43.PubMedPubMedCentralGoogle Scholar
  15. 15.
    D’Souza D. Cannabinoids and psychosis. Int Rev Neurobiol. 2007;78:289–326.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Colizzi M, Bhattacharyya S. Does cannabis composition matter? differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep. 2017;4(2):62–74.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Sherif M, Radhakrishnan R, D’Souza D, Ranganathan M. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):526–38.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Iseger T, Bossong M. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162(1-3):153–61.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Freeman T, Morgan C, Hindocha C, Schafer G, Das R, Curran H. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction. 2014;109(10):1686–94.CrossRefGoogle Scholar
  20. 20.
    ElSohly M, Ross S, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Forensic Sci. 2000;45(1):24–30.Google Scholar
  21. 21.
    ElSohly M, Mehmedic Z, Foster S, Gon C, Chandra S, Church J. Changes in Cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Potter D, Clark P, Brown M. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. 2008;53(1):90–4.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chan G, Hall W, Freeman T, Ferris J, Kelly A, Winstock A. User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate. Drug Alcohol Depend. 2017;178:32–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Raber J, Elzinga S, Kaplan C. Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci. 2015;40(6):797–803.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Fattore L. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):539–48.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Baumann M, Solis EJ, Watterson L, Marusich J, Fantegrossi W, Wiley J. Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci. 2014;34(46):15150–8.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Manseau M, Rajparia A, Joseph A, Azarchi S, Goff D, Satodiya R, Lewis C. Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Subst Use Misuse. 2017;52(6):822–5.CrossRefGoogle Scholar
  28. 28.
    Joseph A, Manseau M, Lalane M, Rajparia A, Lewis C. Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. Am J Drug Alcohol Abuse. 2017;43(1):117–22.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Spaderna M, Addy P, D’Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology. 2013;228(4):525–40.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Zawilska J. “Legal Highs”—An emerging epidemic of novel psychoactive substances. Int Rev Neurobiol. 2015;120:273–300.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Monte A, Bronstein A, Cao D, Heard K, Hoppe J, Hoyte C, Iwanicki J, Lavonas E. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370(4):389–90.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Wiley J, Marusich J, Thomas B. Combination chemistry: structure-activity relationships of novel psychoactive cannabinoids. Curr Top Behav Neurosci. 2017;32:231–48.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Ford B, Tai S, Fantegrossi W, Prather P. Synthetic pot: not your Grandfather’s Marijuana. Trends Pharmacol Sci. 2017;38(3):257–76.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Tai S, Fantegrossi W. Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. Curr Top Behav Neurosci. 2017;32:249–62.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Tait R, Caldicott D, Mountain D, Hill S, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1–13.CrossRefGoogle Scholar
  36. 36.
    Gupta A, D’Souza D. Synthetic cannabinoids: the pharmacokinetics and pharmacodynamics of spice and other synthetic cannabinoids. In: Wolff K, White J, Karch S, editors. The SAGE Handbook of drug & alcohol studies: biological approaches. London: SAGE; 2016.Google Scholar
  37. 37.
    Murray R, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195–204.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29(3):254–63.CrossRefGoogle Scholar
  39. 39.
    Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd Y. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016;30(12):1321–30.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    D’Addario C, Micale V, Di Bartolomeo M, Stark T, Pucci M, Sulcova A, Palazzo M, Babinska Z, Cremaschi L, Drago F, Carlo Altamura A, Maccarrone M, Dell’Osso B. A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophr Res. 2017;188:132–40.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Rohleder C, Leweke F. Cannabinoids and schizophrenia. In: Fattore L, editor. Cannabinoids in neurologic and mental disease. San Diego: Academic Press; 2015. p. 193–204.CrossRefGoogle Scholar
  43. 43.
    Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16(12):705–18.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Nigrete JC. Psychological adverse effects of cannabis smoking: a tentative classification. Can Med Assoc J. 1973;108(2):195–6. passimPubMedPubMedCentralGoogle Scholar
  45. 45.
    Rovai L, Maremmani AG, Pacini M, Pani PP, Rugani F, Lamanna F, Schiavi E, Mautone S, Dell’Osso L, Maremmani I. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv Psichiatr. 2013;48(1):1–9.PubMedPubMedCentralGoogle Scholar
  46. 46.
    D’Souza DC, Radhakrishnan R, Sherif M, Cortes-Briones J, Cahill J, Gupta S, Skosnik PD, Ranganathan M. Cannabinoids and psychosis. Curr Pharm Des. 2016;22(42):6380–91.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Marshall C. The active principle of Indian help; a preliminary communication. Lancet. 1897;1:235–8.CrossRefGoogle Scholar
  48. 48.
    Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry. 1974;30(1):24–7.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Smith DE. Acute and chronic toxicity of marijuana. J Psychedelic Drugs. 1968;2:37–47.CrossRefGoogle Scholar
  50. 50.
    Spencer DJ. Cannabis-induced psychosis. Int J Addict. 1971;6(2):323–6.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Grossman W. Adverse reactions associated with Cannabis products in India. Ann Intern Med. 1969;70(3):529–33.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. JAMA. 1969;210(2):299–302.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Thacore VR. Bhang psychosis. Br J Psychiatry. 1973;123(573):225–9.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Keeler MH, Moore E. Paranoid reactions while using marijuana. Dis Nerv Syst. 1974;35(11):535–6.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Brook M. Psychosis after cannabis abuse. BMJ. 1984;288:1381. Clinical research edCrossRefGoogle Scholar
  56. 56.
    Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr, Harwood S, Franklin R, Cohen MH. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep. 1985;69(1):109–12.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol. 1981;21(8-9 Suppl):43S–50S.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Diasio RB, Ettinger DS, Satterwhite BE. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. J Clin Pharmacol. 1981;21(8-9 Suppl):81S–5S.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Heim ME, Queisser W, Altenburg HP. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 1984;13(2):123–5.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Heim ME, Romer W, Queisser W. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 1981;21(8-9 Suppl):86S–9S.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21(8-9 Suppl):320S–6S.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Kenny JB, Wilkinson PM. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. Clin Oncol. 1982;8(4):335–9.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Laszlo J, Lucas VS Jr, Hanson DC, Cronin CM, Sallan SE. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J Clin Pharmacol. 1981;21(8-9 Suppl):51S–6S.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol. 1984;24(4):155–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Stuart-Harris RC, Mooney CA, Smith IE. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. Clin Oncol. 1983;9(2):143–6.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Roxane—US. Marinol product monograph, PDR Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company; 1998. p. 2544–6.Google Scholar
  67. 67.
    Volkow N, Fowler J, Wolf A, Gillespi H, Metabolic studies of drugs of abuse, NIDA research monograph, National Institute of Drug Abuse, Bethesda, 1991, pp. 47–53.Google Scholar
  68. 68.
    Leweke FM, Schneider U, Thies M, Munte TF, Emrich HM. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology. 1999;142(3):230–5.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Wesnes K, Annas P, Edgar C, Deeprose C, Karlsten R, Philipp A, Kalliomaki J, Segerdahl M. Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers, Journal of psychopharmacology. England: Oxford; 2009.Google Scholar
  70. 70.
    Stambaugh JE Jr, McAdams J, Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J Clin Pharmacol. 1984;24(11-12):480–5.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S, Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev (2015);(11): CD009464.Google Scholar
  72. 72.
    Vallersnes O, Dines A, Wood D, Yates C, Heyerdahl F, Hovda K, Giraudon I, Euro DRG, Dargan P. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011;117(2-3):152–7.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Müller H, Sperling W, Köhrmann M, Huttner H, Kornhuber J, Maler J. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010;118(1-3):309–10.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Benford D, Caplan J. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics. 2011;52(3):295.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction. 2010;105(10):1859–60.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168(10):1119.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Brakoulias V. Products containing synthetic cannabinoids and psychosis. Aust N Z J Psychiatry. 2012;46(3):281–2.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Gunderson E, Haughey H, Ait-Daoud N, Joshi A, Hart C. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21(4):320–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Oluwabusi O, Lobach L, Akhtar U, Youngman B, Ambrosini P. Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol. 2012;22(5):393–5.CrossRefGoogle Scholar
  81. 81.
    Peglow S, Buchner J, Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict. 2012;21(3):287–8.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Tung C, Chiang T, Lam M. Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry. 2012;22(1):31–3.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Glue P, Al-Shaqsi S, Hancock D, Gale C, Strong B, Schep L. Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J. 2013;126(1377):18–23.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534–44.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Haro G, Ripoll C, Ibáñez M, Orengo T, Liaño V, Meneu E, Hernández F, Traver F. Could spice drugs induce psychosis with abnormal movements similar to catatonia? Psychiatry. 2014;77(2):206–8.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Durand D, Delgado L, de la Parra-Pellot D, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: A case report. Clin Schizophr Relat Psychoses. 2015;8(4):205–8.CrossRefGoogle Scholar
  87. 87.
    Roberto A, Lorenzo A, Li K, Young J, Mohan A, Pinnaka S, Lapidus K. First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone. Case Rep Psychiatry. 2016;2016:7257489.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Samaan J, Ferrer G, Akinyemi B, Junquera P, Oms J, Dumenigo R. Synthetic cannabis overdose and withdrawal in a young adult: a case report, commentary on regulation, and review of the literature. Case Rep Psychiatry. 2016;2016:3640549.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis. 2011;30(4):351–8.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31(10):1006–11.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319–27.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Fergusson D, Horwood L, Ridder E. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005;100(3):354–66.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15–21.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330(7481):11.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Tien A, Anthony J. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis. 1990;178(8):473–80.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Saha S, Scott JG, Varghese D, Degenhardt L, Slade T, McGrath JJ. The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. BMC Psychiatry. 2011;11:202.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug and alcohol review. 2003;22(4):453–60.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93(6):837–46.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Mayor’s Committee on Marijuana. The LaGuardia Committee Report: The Marihuana Problem in the City of New York, The New York Academy of Medicine, New York, 1944.Google Scholar
  100. 100.
    Ames F. A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Ment Sci. 1958;104(437):972–99.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, von Spulak F, Korte F. Effects of (--)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia. 1967;11(2):184–8.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Isbell H, Jasinski DR. A comparison of LSD-25 with (-)-delta-9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. Psychopharmacologia. 1969;14(2):115–23.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Renault PF, Schuster CR, Freedman DX, Sikic B, de Mello DN. Repeat administration of marihuana smoke to humans. Arch Gen Psychiatry. 1974;31(1):95–102.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Carlini E, Karniol I, Renault P, Schuster C. Effects of marihuana in laboratory animals and in man. Br J Pharmacol. 1974;50(2):299–309.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Kiplinger G, Manno J. Dose-response relationships to cannabis in human subjects. Pharmacol Rev. 1971;23(4):339–47.PubMedPubMedCentralGoogle Scholar
  106. 106.
    D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–72.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39(10):1607–16.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, van Gerven J. Does olanzapine inhibit the psychomimetic effects of Delta(9)-tetrahydrocannabinol? J Psychopharmacol. 2012;26(10):1307–16.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010;24(11):1697–708.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    D’Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology. 2008;198(4):587–603.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    D’Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Delta(9)-THC in humans. Neuropsychopharmacology. 2012;37(7):1632–46.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Malhi S, Giampietro V, Williams S, Brammer M, Rubia K, Collier DA, McGuire PK. Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. Eur Neuropsychopharmacol. 2015;25(1):26–37.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O’Carroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK. Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012;69(1):27–36.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, Mechelli A, Atakan Z, McGuire P. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009;66(4):442–51.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, CM OC, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764–74.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, Slater M, Godlewska B, Cornish R, Williams J, Di Simplicio M, Igoumenou A, Brenneisen R, Tunbridge EM, Harrison PJ, Harmer CJ, Cowen P, Morrison PD. How cannabis causes paranoia: using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull. 2015;41(2):391–9.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav. 2000;66(1):175–81.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Morrison PD, Stone JM. Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum Psychopharmacol. 2011;26(1):77–80.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Howes OD, Nour MM. Dopamine and the aberrant salience hypothesis of schizophrenia. World Psychiatry. 2016;15(1):3–4.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition; a systematic review. Biol Psychiatry. 2016;79(7):557–67.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425–44.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Miller LL, McFarland D, Cornett TL, Brightwell D. Marijuana and memory impairment: effect on free recall and recognition memory. Pharmacol Biochem Behav. 1977;7(2):99–103.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Marks DF, MacAvoy MG. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology. 1989;99(3):397–401.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Leweke M, Kampmann C, Radwan M, Dietrich DE, Johannes S, Emrich HM, Munte TF. The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology. 1998;37(2):104–11.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Hooker WD, Jones RT. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology. 1987;91(1):20–4.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25(5):757–65.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990;37(3):561–5.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D’Souza DC. Naltrexone does not attenuate the effects of intravenous Delta9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol. 2012:1–14.Google Scholar
  129. 129.
    Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D’Souza DC. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology. 2013;226(2):401–13.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594–608.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of Delta-9-Tetrahydrocannabinol in frequent users of Cannabis. Neuropsychopharmacology. 2008;33(10):2505–16.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Loewe S. The Marihuana Problem in the City of New York, the Mayor’s Committee on Marihuana. Lancaster: Jacques Cattel Press; 1944. p. 149–212.Google Scholar
  133. 133.
    Clark LD, Hughes R, Nakashima EN. Behavioral effects of marihuana: Experimental studies. Arch Gen Psychiatry. 1970;23(3):193.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Kiplinger GF, Manno JE, Rodda BE, Forney RB. Dose-response analysis of the effects of tetrahydrocannabinol in man. Clin Pharmacol Ther. 1971;12(4):650–7.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Evans MA, Martz R, Brown DJ, Rodda BE, Kiplinger GF, Lemberger L, Forney RB. Impairment of performance with low doses of marihuana. Clin Pharmacol Ther. 1973;14(6):936–40.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Rafaelsen L, Christrup H, Bech P, Rafaelsen OJ. Effects of cannabis and alcohol on psychological tests. Nature. 1973;242(5393):117–8.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Milstein SL, MacCannell K, Karr G, Clark S. Marijuana-produced impairments in coordination, Experienced and nonexperienced subjects. J Nerv Ment Dis. 1975;161(1):26–31.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Kvalseth TO. Effects of marijuana on human reaction time and motor control. Percept Mot Skills. 1977;45(3 Pt 1):935–9.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Berghaus G, Schultz E, Szegedi A. Cannabis und fahrtûchtigkeit. Ergebnisse der experimentelle forschung. In: Berghaus G, Krûger HP, editors. Cannabis im Straßenverkehr. Stuttgart: Gustav Fisher Verlag; 1998a. p. 73–97.Google Scholar
  140. 140.
    Berghaus G, Krûger HP, Vollrath M. Beeinträchtigung fahrrelevanter leistungen nach rauchen von cannabis und alcoholconsum. Eine vergleichende metaanalyse experimenteller studien. In: Berghaus G, Krûger HP, editors. Cannabis im Straßenverkehr. Stuttgart: Gustav Fisher Verlag; 1998b. p. 99–111.Google Scholar
  141. 141.
    Dornbush RL, Fink M, Freedman AM. Marijuana, memory, and perception. Am J Psychiatry. 1971;128(2):194–7.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Moskowitz H, Shea R, Burns M. Effect of marihuana on the psychological refractory period. Percept Mot Skills. 1974;38(3):959–62.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Borg J, Gershon S, Alpert M. Dose effects of smoked marihuana on human cognitive and motor functions. Psychopharmacologia. 1975;42(3):211–8.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Peters BA, Lewis EG, Dustman RE, Straight RC, Beck EC. Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta9-tetrahydrocannabinol. Psychopharmacologia. 1976;47(2):141–8.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Schaefer CF, Gunn CG, Dubowski KM. Dose-related heart-rate, perceptual, and decisional changes in man following marihuana smoking. Percept Mot Skills. 1977;44(1):3–16.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Peeke SC, Jones RT, Stone GC. Effects of practice on marijuana-induced changes in reaction time. Psychopharmacology. 1976;48(2):159–63.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Stillman RC, Wolkowitz O, Weingartner H, Waldman I, DeRenzo EV, Wyatt RJ. Marijuana: differential effects on right and left hemisphere functions in man. Life Sci. 1977;21(12):1793–9.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Tapert SF, Schweinsburg AD, Drummond SP, Paulus MP, Brown SA, Yang TT, Frank LR. Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology. 2007;194(2):173–83.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict Behav. 2010;35(11):970–6.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Dumont GJ, van Hasselt JG, de Kam M, van Gerven JM, Touw DJ, Buitelaar JK, Verkes RJ. Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers. J Psychopharmacol. 2011;25(4):478–89.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, Lubman DI, Yucel M. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology. 2011;216(1):131–44.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Ballard ME, Gallo DA, de Wit H. Psychoactive drugs and false memory: comparison of dextroamphetamine and delta-9-tetrahydrocannabinol on false recognition. Psychopharmacology. 2012;219(1):15–24.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Anderson BM, Rizzo M, Block RI, Pearlson GD, O’Leary DS. Sex, drugs, and cognition: effects of marijuana. J Psychoactive Drugs. 2010;42(4):413–24.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Roth WT, Tinklenberg JR, Whitaker CA, Darley CF, Kopell BS, Hollister LE. The effect of marihuana on tracking task performance. Psychopharmacologia. 1973;33(3):259–65.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Burns M, Moskowitz H. Alcohol, marihuana and skills performance, Proceedings International Council on Alcohol, Drugs and Traffic Safety Conference, International Council on Alcohol, Drugs and Traffic Safety, 1981, pp. 954–968.Google Scholar
  156. 156.
    Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, Cassuto Y, Shinar D. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev. 2008;40(3):926–34.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008;33(10):2505–16.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    D’Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology. 2008;198(4):587–603.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis o neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23(2):117–37.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 2004;73(2):109–19.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007;33(1):69–94.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology. 2003;40(5):684–701.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Bramon E, McDonald C, Croft RJ, Landau S, Filbey F, Gruzelier JH, Sham PC, Frangou S, Murray RM. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. NeuroImage. 2005;27(4):960–8.PubMedCrossRefPubMedCentralGoogle Scholar
  164. 164.
    Roth WT, Cannon EH. Some features of the auditory evoked response in schizophrenics. Arch Gen Psychiatry. 1972;27(4):466–71.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Turetsky BI, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol Psychiatry. 1998;43(2):84–96.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Braff DL. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull. 1993;19(2):233–59.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Duncan CC. Event-related brain potentials: a window on information processing in schizophrenia. Schizophr Bull. 1988;14(2):199–203.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Solowij N, Michie PT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci. 2007;32(1):30–52.PubMedPubMedCentralGoogle Scholar
  169. 169.
    Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004;70(2-3):315–29.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol. 2005;16(5-6):487–96.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol. 2008;18(8):569–77.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Uhlhaas PJ, Haenschel C, Nikolić D, Singer W. The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull. 2008;34(5):927–43.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Uhlhaas PJ, Roux F, Rodriguez E, Rotarska-Jagiela A, Singer W. Neural synchrony and the development of cortical networks. Trends Cogn Sci. 2010;14(2):72–80.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11(2):100–13.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D’Souza DC. Delta(9)-THC Disrupts Gamma (gamma)-Band Neural Oscillations in Humans. Neuropsychopharmacology. 2015;40(9):2124–34.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Bocker KB, Hunault CC, Gerritsen J, Kruidenier M, Mensinga TT, Kenemans JL. Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans. J Cogn Neurosci. 2010;22(9):1906–16.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R, Holt D, Wilson D, Sumich A, McGuire P, Murray RM, Kapur S, Ffytche DH. Disruption of frontal theta coherence by Delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology. 2011;36(4):827–36.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Hajos M, Hoffmann WE, Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry. 2008;63(11):1075–83.PubMedCrossRefPubMedCentralGoogle Scholar
  179. 179.
    Stone JM, Morrison PD, Brugger S, Nottage J, Bhattacharyya S, Sumich A, Wilson D, Tunstall N, Feilding A, Brenneisen R, McGuire P, Murray RM, Ffytche DH. Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Mol Psychiatry. 2012;17(6):568–9.PubMedCrossRefPubMedCentralGoogle Scholar
  180. 180.
    Ilan AB, Smith ME, Gevins A. Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology. 2004;176(2):214–22.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Winterer G, Ziller M, Dorn H, Frick K, Mulert C, Wuebben Y, Herrmann W, Coppola R. Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin Neurophysiol. 2000;111(5):837–49.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Winterer G, Weinberger DR. Cortical signal-to-noise ratio: insight into the pathophysiology and genetics of schizophrenia. Clin Neurosci Res. 2003;3(1–2):55–66.CrossRefGoogle Scholar
  183. 183.
    Winterer G, Coppola R, Goldberg TE, Egan MF, Jones DW, Sanchez CE, Weinberger DR. Prefrontal broadband noise, working memory, and genetic risk for schizophrenia. Am J Psychiatr. 2004;161(3):490–500.PubMedCrossRefPubMedCentralGoogle Scholar
  184. 184.
    Diez A, Suazo V, Casado P, Martin-Loeches M, Molina V. Spatial distribution and cognitive correlates of gamma noise power in schizophrenia. Psychol Med. 2013;43(06):1175–85.PubMedCrossRefPubMedCentralGoogle Scholar
  185. 185.
    Díez Á, Suazo V, Casado P, Martín-Loeches M, Perea MV, Molina V. Frontal gamma noise power and cognitive domains in schizophrenia. Psychiatry Res Neuroimaging. 2014;221(1):104–13.CrossRefGoogle Scholar
  186. 186.
    Yang GJ, Murray JD, Repovs G, Cole MW, Savic A, Glasser MF, Pittenger C, Krystal JH, Wang XJ, Pearlson GD, Glahn DC, Anticevic A. Altered global brain signal in schizophrenia. Proc Natl Acad Sci U S A. 2014;111(20):7438–43.PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Skosnik PD, Cortes-Briones JA, Hajos M. It’s all in the rhythm: the role of cannabinoids in neural oscillations and psychosis. Biol Psychiatry. 2016;79(7):568–77.PubMedCrossRefPubMedCentralGoogle Scholar
  188. 188.
    Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D’Souza DC. The psychosis-like effects of delta-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry. 2015;78(11):805–13.Google Scholar
  189. 189.
    Lindemann E, Malamud W. Experimental analysis of the psychopathological effects of intoxicating drug. Am J Psychiatr. 1934;90:853–81.CrossRefGoogle Scholar
  190. 190.
    Pond D. Psychological effects in depressive patients of the marihuana homologue synhexyl. J Neurol Neurosurg Psychiatry. 1948;11(4):271–9.PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748–57.PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Schwarcz G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol. 2009;29(3):255–8.PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Whitfield-Gabrieli S, Fischer AS, Henricks AM, Khokhar JY, Roth RM, Brunette MF, Green AI. Understanding marijuana’s effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. Schizophr Res. 2017;Google Scholar
  194. 194.
    Chopra GS. Studies on psycho-clinical aspects of long-term marihuana use in 124 cases. Int J Addict. 1973;8(6):1015–26.PubMedCrossRefPubMedCentralGoogle Scholar
  195. 195.
    Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510–5.PubMedCrossRefPubMedCentralGoogle Scholar
  196. 196.
    Bernhardson G, Gunne LM. Forty-six cases of psychosis in cannabis abusers. Int J Addict. 1972;7(1):9–16.PubMedCrossRefPubMedCentralGoogle Scholar
  197. 197.
    Harding T, Knight F. Marihuana-modified mania. Arch Gen Psychiatry. 1973;29(5):635–7.PubMedCrossRefPubMedCentralGoogle Scholar
  198. 198.
    Mathers DC, Ghodse AH, Caan AW, Scott SA. Cannabis use in a large sample of acute psychiatric admissions. Br J Addict. 1991;86(6):779–84.PubMedCrossRefPubMedCentralGoogle Scholar
  199. 199.
    Carney MW, Bacelle L, Robinson B. Psychosis after cannabis abuse. Br Med J (Clin Res Ed). 1984;288(6423):1047.CrossRefGoogle Scholar
  200. 200.
    Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry. 1972;27:133–6.PubMedCrossRefPubMedCentralGoogle Scholar
  201. 201.
    Wylie AS, Scott RT, Burnett SJ. Psychosis due to “skunk”. BMJ. 1995;311(6997):125.PubMedPubMedCentralCrossRefGoogle Scholar
  202. 202.
    Rottanburg D, Robins AH, Ben-Arie O, Teggin A, Elk R. Cannabis-associated psychosis with hypomanic features. Lancet. 1982;2(8312):1364–6.PubMedCrossRefPubMedCentralGoogle Scholar
  203. 203.
    Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352(9140):1611–6.PubMedCrossRefPubMedCentralGoogle Scholar
  204. 204.
    Oliveira P, Morais ASF, Madeira N. Synthetic cannabis analogues and suicidal behavior: case report. J Addict Med. 2017;Google Scholar
  205. 205.
    Keller CJ, Chen EC, Brodsky K, Yoon JH. A case of butane hash oil (marijuana wax)-induced psychosis. Subst Abus. 2016;37(3):384–6.PubMedCrossRefPubMedCentralGoogle Scholar
  206. 206.
    Pierre JM, Gandal M, Son M. Cannabis-induced psychosis associated with high potency “wax dabs”. Schizophr Res. 2016;172(1-3):211–2.PubMedCrossRefPubMedCentralGoogle Scholar
  207. 207.
    Basu D, Malhotra A, Bhagat A, Varma VK. Cannabis psychosis and acute schizophrenia. a case-control study from India. Eur Addict Res. 1999;5(2):71–3.PubMedCrossRefPubMedCentralGoogle Scholar
  208. 208.
    Chaudry HR, Moss HB, Bashir A, Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict. 1991;86(9):1075–81.PubMedCrossRefPubMedCentralGoogle Scholar
  209. 209.
    Cohen SI. Cannabis consumption and schizophrenia. Br J Psychiatry. 1994;165(3):410–1.PubMedCrossRefPubMedCentralGoogle Scholar
  210. 210.
    Thacore VR, Shukla SR. Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry. 1976;33(3):383–6.PubMedCrossRefPubMedCentralGoogle Scholar
  211. 211.
    Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. JAMA. 1971;216(3):486–92.PubMedCrossRefPubMedCentralGoogle Scholar
  212. 212.
    Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169(4):389–96.PubMedCrossRefPubMedCentralGoogle Scholar
  213. 213.
    Caton CL, Hasin DS, Shrout PE, Drake RE, Dominguez B, First MB, Samet S, Schanzer B. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry. 2007;190:105–11.PubMedCrossRefPubMedCentralGoogle Scholar
  214. 214.
    Chen WL, Hsieh CH, Chang HT, Hung CC, Chan CH. The epidemiology and progression time from transient to permanent psychiatric disorders of substance-induced psychosis in Taiwan. Addict Behav. 2015;47:1–4.PubMedCrossRefPubMedCentralGoogle Scholar
  215. 215.
    Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. J Clin Psychiatry. 2014;75(4):349–56.PubMedCrossRefPubMedCentralGoogle Scholar
  216. 216.
    Alderson HL, Semple DM, Blayney C, Queirazza F, Chekuri V, Lawrie SM. Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. Psychol Med. 2017:1–8.Google Scholar
  217. 217.
    Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18, 478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94–9.PubMedCrossRefPubMedCentralGoogle Scholar
  218. 218.
    Thompson A, Marwaha S, Winsper C, Everard L, Jones PB, Fowler D, Amos T, Freemantle N, Singh SP, Marshall M, Sharma V, Birchwood M. Short-term outcome of substance-induced psychotic disorder in a large UK first episode psychosis cohort. Acta Psychiatr Scand. 2016;134(4):321–8.PubMedCrossRefPubMedCentralGoogle Scholar
  219. 219.
    Starzer MSK, Nordentoft M, Hjorthoj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry (2017) appiajp201717020223.Google Scholar
  220. 220.
    Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483–6.PubMedCrossRefPubMedCentralGoogle Scholar
  221. 221.
    Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.PubMedPubMedCentralCrossRefGoogle Scholar
  222. 222.
    Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med. 2012;42(6):1321–8.PubMedCrossRefPubMedCentralGoogle Scholar
  223. 223.
    Rounsaville BJ. DSM-V research agenda: substance abuse/psychosis comorbidity. Schizophr Bull. 2007;33(4):947–52.PubMedPubMedCentralCrossRefGoogle Scholar
  224. 224.
    Carney ST, Lloyd ML, MacKinnon SE, Newton DC, Jones JD, Howlett AC, Norford DC. Cannabinoid regulation of nitric oxide synthase I (nNOS) in neuronal cells. J Neuroimmune Pharmacol. 2009;4(3):338–49.PubMedPubMedCentralCrossRefGoogle Scholar
  225. 225.
    Varma L. Cannabis psychosis. Indian J Psychiatry. 1972;14:241–55.Google Scholar
  226. 226.
    Pauselli L. Cannabis-induced psychotic disorders. In: Compton M, Manseau M, editors. The complex connection between Cannabis and Schizophrenia. Elsevier: Academic Press; 2018. p. 183–97.CrossRefGoogle Scholar
  227. 227.
    Caton CL, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, Schanzer B. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry. 2005;62(2):137–45.PubMedCrossRefPubMedCentralGoogle Scholar
  228. 228.
    Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr Res. 2007;93(1-3):203–10.PubMedCrossRefPubMedCentralGoogle Scholar
  229. 229.
    Rubio G, Marin-Lozano J, Ferre F, Martinez-Gras I, Rodriguez-Jimenez R, Sanz J, Jimenez-Arriero MA, Carrasco JL, Lora D, Jurado R, Lopez-Trabada JR, Palomo T. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis. Compr Psychiatry. 2012;53(8):1063–70.PubMedCrossRefPubMedCentralGoogle Scholar
  230. 230.
    Baldacchino A, Hughes Z, Kehoe M, Blair H, Teh Y, Windeatt S, Crome IB. Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. Am J Addict. 2012;21(Suppl 1):S88–98.PubMedCrossRefPubMedCentralGoogle Scholar
  231. 231.
    Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry. 2008;65(11):1269–74.PubMedCrossRefPubMedCentralGoogle Scholar
  232. 232.
    Dragogna F, Mauri MC, Marotta G, Armao FT, Brambilla P, Altamura AC. Brain metabolism in substance-induced psychosis and schizophrenia: a preliminary PET study. Neuropsychobiology. 2014;70(4):195–202.PubMedCrossRefPubMedCentralGoogle Scholar
  233. 233.
    Morales-Munoz I, Jurado-Barba R, Ponce G, Martinez-Gras I, Jimenez-Arriero MA, Moratti S, Rubio G. Characterizing cannabis-induced psychosis: a study with prepulse inhibition of the startle reflex. Psychiatry Res. 2014;220(1-2):535–40.PubMedCrossRefPubMedCentralGoogle Scholar
  234. 234.
    Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3.PubMedPubMedCentralCrossRefGoogle Scholar
  235. 235.
    van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319–27.PubMedCrossRefPubMedCentralGoogle Scholar
  236. 236.
    Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.PubMedPubMedCentralCrossRefGoogle Scholar
  237. 237.
    Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet. 2002;114(8):949–55.PubMedCrossRefPubMedCentralGoogle Scholar
  238. 238.
    Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549–56.PubMedCrossRefPubMedCentralGoogle Scholar
  239. 239.
    Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–9.PubMedPubMedCentralCrossRefGoogle Scholar
  240. 240.
    Millman RB, Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. Psychiatr Clin North Am. 1986;9(3):533–45.PubMedCrossRefPubMedCentralGoogle Scholar
  241. 241.
    Halikas J, Weller R, Morse C. Effects of regular marijuana use on sexual performance. J Psychoactive Drugs. 1982;14(1-2):59–70.PubMedCrossRefPubMedCentralGoogle Scholar
  242. 242.
    Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. J Psychiatr Nurs Ment Health Serv. 1971;9(6):9–16.PubMedPubMedCentralGoogle Scholar
  243. 243.
    Lawn W, Freeman TP, Pope RA, Joye A, Harvey L, Hindocha C, Mokrysz C, Moss A, Wall MB, Bloomfield MA, Das RK, Morgan CJ, Nutt DJ, Curran HV. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology. 2016;233(19-20):3537–52.PubMedPubMedCentralCrossRefGoogle Scholar
  244. 244.
    Nader DA, Sanchez ZM. Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. Am J Drug Alcohol Abuse. 2017:1–15.Google Scholar
  245. 245.
    Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426–45.PubMedCrossRefPubMedCentralGoogle Scholar
  246. 246.
    Pope HJ, Gruber A, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995;38(1):25–34.PubMedCrossRefPubMedCentralGoogle Scholar
  247. 247.
    Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909–15.PubMedCrossRefPubMedCentralGoogle Scholar
  248. 248.
    Bolla K, Brown K, Eldreth D, Tate K, Cadet J. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337–43.PubMedCrossRefPubMedCentralGoogle Scholar
  249. 249.
    Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav. 2005;81(2):319–30.PubMedCrossRefPubMedCentralGoogle Scholar
  250. 250.
    Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1(1):81–98.CrossRefGoogle Scholar
  251. 251.
    Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–7.PubMedCrossRefPubMedCentralGoogle Scholar
  252. 252.
    Pope HG Jr, Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep. 2001;3(6):507–12.PubMedCrossRefPubMedCentralGoogle Scholar
  253. 253.
    Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1–8.PubMedPubMedCentralCrossRefGoogle Scholar
  254. 254.
    Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot: a review of the association between Cannabis and psychosis. Front Psychol. 2014;5:54.Google Scholar
  255. 255.
    Solowij N. Psychotomimetic and cognitive effects of Cannabis use in the general population. In: Compton M, Manseau M, editors. The complex connection between Cannabis and Schizophrenia. Elsevier: Academic Press; 2018. p. 129–55.CrossRefGoogle Scholar
  256. 256.
    Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293–306.PubMedCrossRefPubMedCentralGoogle Scholar
  257. 257.
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657–64.PubMedPubMedCentralCrossRefGoogle Scholar
  258. 258.
    Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci Biobehav Rev. 2017;72:310–24.PubMedCrossRefPubMedCentralGoogle Scholar
  259. 259.
    Cohen K, Kapitany-Foveny M, Mama Y, Arieli M, Rosca P, Demetrovics Z, Weinstein A. The effects of synthetic cannabinoids on executive function. Psychopharmacology. 2017;234(7):1121–34.PubMedCrossRefPubMedCentralGoogle Scholar
  260. 260.
    Schnakenberg Martin AM, Bonfils KA, Davis BJ, Smith EA, Schuder K, Lysaker PH. Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. Schizophr Res Cogn. 2016;6:15–21.PubMedPubMedCentralCrossRefGoogle Scholar
  261. 261.
    Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, Kiang M, Remington G, George TP. Effects of extended Cannabis abstinence on cognitive outcomes in cannabis dependent patients with schizophrenia vs non-psychiatric controls. Neuropsychopharmacology. 2017;42(11):2259–71.PubMedPubMedCentralCrossRefGoogle Scholar
  262. 262.
    Rentzsch J, Penzhorn A, Kernbichler K, Plockl D, Gomez-Carrillo de Castro A, Gallinat J, Jockers-Scherubl MC. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp Neurol. 2007;205(1):241–9.PubMedCrossRefPubMedCentralGoogle Scholar
  263. 263.
    de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res. 2007;97(1-3):137–51.PubMedCrossRefPubMedCentralGoogle Scholar
  264. 264.
    Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE Jr. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res. 2008;158(2):226–47.PubMedCrossRefPubMedCentralGoogle Scholar
  265. 265.
    Zachariou M, Dissanayake DW, Coombes S, Owen MR, Mason R. Sensory gating and its modulation by cannabinoids: electrophysiological, computational and mathematical analysis. Cogn Neurodyn. 2008;2(2):159–70.PubMedPubMedCentralCrossRefGoogle Scholar
  266. 266.
    Dissanayake DW, Zachariou M, Marsden CA, Mason R. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2. Neuropharmacology. 2008;55(8):1397–404.PubMedCrossRefPubMedCentralGoogle Scholar
  267. 267.
    Patrick G, Straumanis JJ, Struve FA, Fitz-Gerald MJ, Leavitt J, Manno JE. Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biol Psychiatry. 1999;45(10):1307–12.PubMedCrossRefPubMedCentralGoogle Scholar
  268. 268.
    Patrick G, Struve FA. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalogr. 2000;31(2):88–93.PubMedCrossRefPubMedCentralGoogle Scholar
  269. 269.
    Naatanen R, Alho K. Generators of electrical and magnetic mismatch responses in humans. Brain Topogr. 1995;7(4):315–20.PubMedCrossRefPubMedCentralGoogle Scholar
  270. 270.
    Rinne T, Alho K, Ilmoniemi RJ, Virtanen J, Naatanen R. Separate time behaviors of the temporal and frontal mismatch negativity sources. NeuroImage. 2000;12(1):14–9.PubMedCrossRefPubMedCentralGoogle Scholar
  271. 271.
    Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, Srihari VH, Mathalon DH. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry. 2013;75(6):459–69.PubMedPubMedCentralCrossRefGoogle Scholar
  272. 272.
    Pesa N, Hermens DF, Battisti RA, Kaur M, Hickie IB, Solowij N. Delayed preattentional functioning in early psychosis patients with cannabis use. Psychopharmacology. 2012;222(3):507–18.PubMedCrossRefPubMedCentralGoogle Scholar
  273. 273.
    Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res. 2007;97(1-3):109–17.PubMedPubMedCentralCrossRefGoogle Scholar
  274. 274.
    Roser P, Della B, Norra C, Uhl I, Brune M, Juckel G. Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci. 2010;260(6):491–8.PubMedCrossRefPubMedCentralGoogle Scholar
  275. 275.
    Greenwood LM, Broyd SJ, Croft R, Todd J, Michie PT, Johnstone S, Murray R, Solowij N. Chronic effects of Cannabis use on the auditory mismatch negativity. Biol Psychiatry. 2013;75(6):449–58.PubMedCrossRefPubMedCentralGoogle Scholar
  276. 276.
    Rentzsch J, Buntebart E, Stadelmeier A, Gallinat J, Jockers-Scherubl MC. Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophr Res. 2011;130(1-3):222–7.PubMedCrossRefPubMedCentralGoogle Scholar
  277. 277.
    Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D’Souza DC. Delta9-THC Disrupts Gamma (gamma)-Band Neural Oscillations in Humans. Neuropsychopharmacology. 2015;40(9):2124–34.PubMedPubMedCentralCrossRefGoogle Scholar
  278. 278.
    Edwards CR, Skosnik PD, Steinmetz AB, O’Donnell BF, Hetrick WP. Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations. Behav Neurosci. 2009;123(4):894–904.PubMedPubMedCentralCrossRefGoogle Scholar
  279. 279.
    Skosnik PD, D’Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, O’Donnell BF. The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology. 2012;37(10):2184–93.PubMedPubMedCentralCrossRefGoogle Scholar
  280. 280.
    Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O’Donnell BF. Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry. 2006;163(10):1798–805.PubMedCrossRefPubMedCentralGoogle Scholar
  281. 281.
    Skosnik PD, Krishnan GP, D’Souza DC, Hetrick WP, O’Donnell BF. Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users. Neuropsychopharmacology. 2014;39(13):3087–99.PubMedPubMedCentralCrossRefGoogle Scholar
  282. 282.
    Herning RI, Better W, Tate K, Cadet JL. EEG deficits in chronic marijuana abusers during monitored abstinence: preliminary findings. Ann N Y Acad Sci. 2003;993:75–8. discussion 79-81.PubMedCrossRefPubMedCentralGoogle Scholar
  283. 283.
    Hanna RC, Perez JM, Ghose S. Cannabis and development of dual diagnoses: A literature review. Am J Drug Alcohol Abuse. 2017;43(4):442–55.PubMedPubMedCentralCrossRefGoogle Scholar
  284. 284.
    Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence.[see comment]. Br J Psychiatry. 2004;184:110–7.PubMedCrossRefPubMedCentralGoogle Scholar
  285. 285.
    Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.PubMedCrossRefPubMedCentralGoogle Scholar
  286. 286.
    Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of Cannabis use. Schizophr Bull. 2005;31(3):608–12.PubMedCrossRefPubMedCentralGoogle Scholar
  287. 287.
    Aiello AE, Larson EL. Causal inference: the case of hygiene and health. Am J Infect Control. 2002;30(8):503–11.PubMedCrossRefPubMedCentralGoogle Scholar
  288. 288.
    Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMedPubMedCentralGoogle Scholar
  289. 289.
    Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction. 2005;100(5):612–8.PubMedCrossRefPubMedCentralGoogle Scholar
  290. 290.
    Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkotter J, Linszen DH, E. group. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012;125(1):45–53.PubMedCrossRefPubMedCentralGoogle Scholar
  291. 291.
    Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M. Cannabis use disorder and age at onset of psychosis--a study in first-episode patients. Schizophr Res. 2011;129(1):52–6.PubMedCrossRefPubMedCentralGoogle Scholar
  292. 292.
    Cunha PJ, Rosa PG, Ayres Ade M, Duran FL, Santos LC, Scazufca M, Menezes PR, dos Santos B, Murray RM, Crippa JA, Busatto GF, Schaufelberger MS. Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res. 2013;147(2-3):209–15.PubMedCrossRefPubMedCentralGoogle Scholar
  293. 293.
    Allebeck P, Adamsson C, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County.[erratum appears in Acta Psychiatr Scand 1993 Oct;88(4):304]. Acta Psychiatr Scand. 1993;88(1):21–4.PubMedCrossRefPubMedCentralGoogle Scholar
  294. 294.
    Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273–9.PubMedCrossRefPubMedCentralGoogle Scholar
  295. 295.
    Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996;40(11):1155–63.PubMedCrossRefPubMedCentralGoogle Scholar
  296. 296.
    Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry. 2000;34(3):468–75.PubMedCrossRefPubMedCentralGoogle Scholar
  297. 297.
    Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci. 2002;252(2):86–92.PubMedCrossRefPubMedCentralGoogle Scholar
  298. 298.
    Buhler B, Hambrecht M, Loffler W, W. an der Heiden, H. Hafner. Precipitation and determination of the onset and course of schizophrenia by substance abuse--a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res. 2002;54(3):243–51.PubMedCrossRefPubMedCentralGoogle Scholar
  299. 299.
    Mauri MC, Volonteri LS, De Gaspari IF, Colasanti A, Brambilla MA, Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health. 2006;2:4.PubMedPubMedCentralCrossRefGoogle Scholar
  300. 300.
    Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K, Bertani M, Bissoli S, Lazzarotto L, Marrella G, Lamonaca D, Riolo R, Gardellin F, Urbani A, Tansella M, Ruggeri M, P.-V. Group. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res. 2013;47(4):438–44.PubMedCrossRefPubMedCentralGoogle Scholar
  301. 301.
    Allegri F, Belvederi Murri M, Paparelli A, Marcacci T, Braca M, Menchetti M, Michetti R, Berardi D, Tarricone I. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res. 2013;210(1):368–70.PubMedCrossRefPubMedCentralGoogle Scholar
  302. 302.
    Myles H, Myles N, Large M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust N Z J Psychiatry. 2016;50(3):208–19.PubMedCrossRefPubMedCentralGoogle Scholar
  303. 303.
    Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R, McCormack J, Lorell BS, Kane J. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr Res. 2010;120(1-3):101–7.PubMedPubMedCentralCrossRefGoogle Scholar
  304. 304.
    Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Investigators G. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychol Med. 2012;42(9):1903–11.PubMedCrossRefPubMedCentralGoogle Scholar
  305. 305.
    Myles N, Newall H, Nielssen O, Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des. 2012;18(32):5055–69.PubMedCrossRefPubMedCentralGoogle Scholar
  306. 306.
    Wilkinson ST, Radhakrishnan R, D’Souza DC. Impact of Cannabis use on the development of psychotic disorders. Curr Addict Rep. 2014;1(2):115–28.PubMedPubMedCentralCrossRefGoogle Scholar
  307. 307.
    Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, Rahaman N, Joyce J, Hinton M, Johnson S, Young AH, MiData C. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44(3):499–506.PubMedCrossRefPubMedCentralGoogle Scholar
  308. 308.
    Caton CL, Xie H, Drake RE, McHugo G. Gender differences in psychotic disorders with concurrent substance use. J Dual Diagn. 2014;10(4):177–86.PubMedPubMedCentralCrossRefGoogle Scholar
  309. 309.
    Frascarelli M, Quartini A, Tomassini L, Russo P, Zullo D, Manuali G, De Filippis S, Bersani G. Cannabis use related to early psychotic onset: Role of premorbid function. Neurosci Lett. 2016;633:55–61.PubMedCrossRefPubMedCentralGoogle Scholar
  310. 310.
    Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health. 1987;77(4):425–31.PubMedPubMedCentralCrossRefGoogle Scholar
  311. 311.
    Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, Madden PA, Medland SE, Wray NR, Martin NG. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201–4.PubMedPubMedCentralCrossRefGoogle Scholar
  312. 312.
    Verweij KJ, Abdellaoui A, Nivard MG, Sainz Cort A, Ligthart L, Draisma HH, Minica CC, C. International Cannabis. Short communication: genetic association between schizophrenia and cannabis use. Drug Alcohol Depend. 2017;171:117–21.PubMedPubMedCentralCrossRefGoogle Scholar
  313. 313.
    Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, Smith DJ, Pell JP, Sattar N, Pare G, Holmes MV. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2017;23(5):1287–92.PubMedPubMedCentralCrossRefGoogle Scholar
  314. 314.
    Gage SH, Jones HJ, Burgess S, Bowden J, Davey Smith G, Zammit S, Munafo MR. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med. 2017;47(5):971–80.PubMedCrossRefPubMedCentralGoogle Scholar
  315. 315.
    Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 2015;45(2):407–14.PubMedCrossRefPubMedCentralGoogle Scholar
  316. 316.
    Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013;151(1-3):197–202.CrossRefGoogle Scholar
  317. 317.
    Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24(1):51–64.PubMedCrossRefPubMedCentralGoogle Scholar
  318. 318.
    Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, Reed TA, Amar P, Kaslow NJ, Walker EF, Compton MT. Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res. 2016;171(1-3):62–7.PubMedPubMedCentralCrossRefGoogle Scholar
  319. 319.
    Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.[comment]. BMJ. 2002;325(7374):1199.PubMedPubMedCentralCrossRefGoogle Scholar
  320. 320.
    Gage SH, Hickman M, Heron J, Munafo MR, Lewis G, Macleod J, Zammit S. Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychol Med. 2014;44(16):3435–44.PubMedPubMedCentralCrossRefGoogle Scholar
  321. 321.
    Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61.PubMedCrossRefPubMedCentralGoogle Scholar
  322. 322.
    Myles N, Newall H, Compton MT, Curtis J, Nielssen O, Large M. The age at onset of psychosis and tobacco use: a systematic meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2012;47(8):1243–50.PubMedCrossRefPubMedCentralGoogle Scholar
  323. 323.
    Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep. 2016;18(2):12.PubMedCrossRefPubMedCentralGoogle Scholar
  324. 324.
    Ouellet-Plamondon C, Abdel-Baki A, Salvat E, Potvin S. Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. Psychol Med. 2017:1–11.Google Scholar
  325. 325.
    Dubertret C, Bidard I, Ades J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res. 2006;86(1-3):284–90.PubMedCrossRefPubMedCentralGoogle Scholar
  326. 326.
    Brook DW, Brook JS, Zhang C, Cohen P, Whiteman M. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry. 2002;59(11):1039–44.PubMedCrossRefPubMedCentralGoogle Scholar
  327. 327.
    van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007;102(8):1251–60.CrossRefGoogle Scholar
  328. 328.
    Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810.PubMedCrossRefPubMedCentralGoogle Scholar
  329. 329.
    Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry. 2012;12:112.PubMedPubMedCentralCrossRefGoogle Scholar
  330. 330.
    Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 2013;108(1):124–33.PubMedCrossRefPubMedCentralGoogle Scholar
  331. 331.
    Blanco C, Hasin DS, Wall MM, Florez-Salamanca L, Hoertel N, Wang S, Kerridge BT, Olfson M. Cannabis use and risk of psychiatric disorders: prospective evidence from a US National Longitudinal Study. JAMA Psychiatry. 2016;73(4):388–95.PubMedCrossRefPubMedCentralGoogle Scholar
  332. 332.
    Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. 2010;169(4):1651–61.PubMedPubMedCentralCrossRefGoogle Scholar
  333. 333.
    Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678–82.PubMedCrossRefPubMedCentralGoogle Scholar
  334. 334.
    Bartos M, Elgueta C. Functional characteristics of parvalbumin-and cholecystokinin-expressing basket cells. J Physiol. 2012;590(4):669–81.PubMedPubMedCentralCrossRefGoogle Scholar
  335. 335.
    Farkas I, Kallo I, Deli L, Vida B, Hrabovszky E, Fekete C, Moenter SM, Watanabe M, Liposits Z. Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology. 2010;151(12):5818–29.PubMedPubMedCentralCrossRefGoogle Scholar
  336. 336.
    Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005;10(5):434–49.PubMedCrossRefPubMedCentralGoogle Scholar
  337. 337.
    Weinberger DR. On the plausibility of “the neurodevelopmental hypothesis” of schizophrenia. Neuropsychopharmacology. 1996;14(3 Suppl):1S–11S.PubMedCrossRefPubMedCentralGoogle Scholar
  338. 338.
    O’Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol. 2004;18(4):502–8.PubMedCrossRefPubMedCentralGoogle Scholar
  339. 339.
    Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology. 2008;33(5):1113–26.PubMedCrossRefPubMedCentralGoogle Scholar
  340. 340.
    Cha YM, White AM, Kuhn CM, Wilson WA, Swartzwelder HS. Differential effects of delta9-THC on learning in adolescent and adult rats. Pharmacol Biochem Behav. 2006;83(3):448–55.PubMedCrossRefPubMedCentralGoogle Scholar
  341. 341.
    Schneider M, Schomig E, Leweke FM. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol. 2008;13(3-4):345–57.PubMedCrossRefPubMedCentralGoogle Scholar
  342. 342.
    Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008;13(2):253–63.PubMedCrossRefPubMedCentralGoogle Scholar
  343. 343.
    Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem Behav. 2007;86(2):189–99.PubMedCrossRefPubMedCentralGoogle Scholar
  344. 344.
    Rice D, Barone S Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect. 2000;108(Suppl 3):511–33.PubMedPubMedCentralCrossRefGoogle Scholar
  345. 345.
    Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist. 2007;13(2):109–14.PubMedCrossRefPubMedCentralGoogle Scholar
  346. 346.
    Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di Marzo V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzman M, Lu HC, Galve-Roperh I, Harkany T. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008;105(25):8760–5.PubMedPubMedCentralCrossRefGoogle Scholar
  347. 347.
    Watson S, Chambers D, Hobbs C, Doherty P, Graham A. The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Mol Cell Neurosci. 2008;38(1):89–97.PubMedCrossRefPubMedCentralGoogle Scholar
  348. 348.
    Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A. 2005;102(52):19115–20.PubMedPubMedCentralCrossRefGoogle Scholar
  349. 349.
    Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316(5828):1212–6.PubMedCrossRefPubMedCentralGoogle Scholar
  350. 350.
    Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzman M, Galve-Roperh I. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci. 2006;26(5):1551–61.PubMedCrossRefPubMedCentralGoogle Scholar
  351. 351.
    Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci. 2007;28(2):83–92.PubMedCrossRefPubMedCentralGoogle Scholar
  352. 352.
    Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000;23(1):14–20.PubMedCrossRefPubMedCentralGoogle Scholar
  353. 353.
    Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, Childs J, Greenberg DA. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol. 2004;66(2):204–8.PubMedCrossRefPubMedCentralGoogle Scholar
  354. 354.
    Ruiz-Veguilla M, Barrigon ML, Hernandez L, Rubio JL, Gurpegui M, Sarramea F, Cervilla J, Gutierrez B, James A, Ferrin M. Dose-response effect between cannabis use and psychosis liability in a non-clinical population: evidence from a snowball sample. J Psychiatr Res. 2013;47(8):1036–43.PubMedCrossRefPubMedCentralGoogle Scholar
  355. 355.
    Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O’Donovan MC, Corvin A, Cichon S, Sullivan PF. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015;20(5):555–62.PubMedPubMedCentralCrossRefGoogle Scholar
  356. 356.
    Vinkers CH, Van Gastel WA, Schubart CD, Van Eijk KR, Luykx JJ, Van Winkel R, Joels M, Ophoff RA, Boks MP, Genetic R, O.U.o.P. Investigators, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism. Schizophr Res. 2013;150(1):303–11.PubMedCrossRefPubMedCentralGoogle Scholar
  357. 357.
    Alemany S, Arias B, Fatjo-Vilas M, Villa H, Moya J, Ibanez MI, Ortet G, Gasto C, Fananas L. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand. 2014;129(1):54–62.PubMedCrossRefPubMedCentralGoogle Scholar
  358. 358.
    Henquet C, Rosa A, Delespaul P, Papiol S, Fananas L, van Os J, Myin-Germeys I. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of ‘switching on’ hallucinations in the flow of daily life. Acta Psychiatr Scand. 2009;119(2):156–60.PubMedCrossRefPubMedCentralGoogle Scholar
  359. 359.
    Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117–27.PubMedCrossRefPubMedCentralGoogle Scholar
  360. 360.
    Costas J, Sanjuan J, Ramos-Rios R, Paz E, Agra S, Tolosa A, Paramo M, Brenlla J, Arrojo M. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr Res. 2011;127(1-3):22–7.PubMedCrossRefPubMedCentralGoogle Scholar
  361. 361.
    Estrada G, Fatjo-Vilas M, Munoz MJ, Pulido G, Minano MJ, Toledo E, Illa JM, Martin M, Miralles ML, Miret S, Campanera S, Bernabeu C, Navarro ME, Fananas L. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand. 2011;123(6):485–92.PubMedPubMedCentralCrossRefGoogle Scholar
  362. 362.
    Kantrowitz JT, Nolan KA, Sen S, Simen AA, Lachman HM, Bowers MB Jr. Adolescent cannabis use, psychosis and catechol-O-methyltransferase genotype in African Americans and Caucasians. Psychiatr Q. 2009;80(4):213–8.PubMedPubMedCentralCrossRefGoogle Scholar
  363. 363.
    Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry. 2011;199(5):380–5.PubMedPubMedCentralCrossRefGoogle Scholar
  364. 364.
    Zammit S, Spurlock G, Williams H, Norton N, Williams N, O’Donovan MC, Owen MJ. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry. 2007;191:402–7.PubMedCrossRefPubMedCentralGoogle Scholar
  365. 365.
    van Winkel R, Genetic R, I. Outcome of Psychosis. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011;68(2):148–57.PubMedPubMedCentralCrossRefGoogle Scholar
  366. 366.
    Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Facorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des. 2012;18(32):5024–35.PubMedCrossRefPubMedCentralGoogle Scholar
  367. 367.
    Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, Williams S, Brammer M, Collier DA, McGuire PK. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry. 2012;17(12):1152–5.PubMedCrossRefPubMedCentralGoogle Scholar
  368. 368.
    Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 2012;72(10):811–6.PubMedCrossRefPubMedCentralGoogle Scholar
  369. 369.
    Liemburg EJ, Bruins J, van Beveren N, Islam MA, Alizadeh BZ, G. investigators. Cannabis and a lower BMI in psychosis: What is the role of AKT1? Schizophr Res. 2016;176(2-3):95–9.PubMedCrossRefPubMedCentralGoogle Scholar
  370. 370.
    Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology. 2007;192(3):325–36.PubMedCrossRefPubMedCentralGoogle Scholar
  371. 371.
    Decoster J, van Os J, Kenis G, Henquet C, Peuskens J, De Hert M, van Winkel R. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3):363–9.PubMedCrossRefPubMedCentralGoogle Scholar
  372. 372.
    Bogdan R, Winstone JM, Agrawal A. Genetic and environmental factors associated with Cannabis involvement. Curr Addict Rep. 2016;3(2):199–213.PubMedPubMedCentralCrossRefGoogle Scholar
  373. 373.
    Nesvag R, Reichborn-Kjennerud T, Gillespie NA, Knudsen GP, Bramness JG, Kendler KS, Ystrom E. Genetic and environmental contributions to the association between Cannabis use and psychotic-like experiences in young adult twins. Schizophr Bull. 2017;43(3):644–53.PubMedPubMedCentralGoogle Scholar
  374. 374.
    Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull. 2008;34(3):580–5.PubMedCrossRefPubMedCentralGoogle Scholar
  375. 375.
    Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D, Fitzpatrick C, Cannon M. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med. 2010;40(10):1627–34.PubMedCrossRefPubMedCentralGoogle Scholar
  376. 376.
    Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, van Os J, Bakoula C, Henquet C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med. 2012;42(1):149–59.PubMedCrossRefPubMedCentralGoogle Scholar
  377. 377.
    Kuepper R, Henquet C, Lieb R, Wittchen HU, van Os J. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr Res. 2011;131(1-3):262–3.PubMedCrossRefPubMedCentralGoogle Scholar
  378. 378.
    Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol Med. 2011;41(10):2121–9.PubMedCrossRefPubMedCentralGoogle Scholar
  379. 379.
    Cougnard A, Marcelis M, Myin-Germeys I, De Graaf R, Vollebergh W, Krabbendam L, Lieb R, Wittchen HU, Henquet C, Spauwen J, Van Os J. Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol Med. 2007;37(4):513–27.PubMedCrossRefPubMedCentralGoogle Scholar
  380. 380.
    Wan CR, Broussard B. Cannabis use as a determinant of earlier age at onset of Schizophrenia and related psychotic disorders. In: Compton M, Manseau M, editors. The complex connection between Cannabis and Schizophrenia. Elsevier: Academic Press; 2018. p. 247–69.Google Scholar
  381. 381.
    Goldberger C, Dervaux A, Gourion D, Bourdel MC, Loo H, Laqueille X, Krebs MO. Variable individual sensitivity to cannabis in patients with schizophrenia. Int J Neuropsychopharmacol. 2010;13(9):1145–54.PubMedCrossRefPubMedCentralGoogle Scholar
  382. 382.
    Leeson VC, Harrison I, Ron MA, Barnes TR, Joyce EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull. 2012;38(4):873–80.PubMedCrossRefPubMedCentralGoogle Scholar
  383. 383.
    Bechtold J, Hipwell A, Lewis DA, Loeber R, Pardini D. Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms. Am J Psychiatry. 2016;173(8):781–9.PubMedPubMedCentralCrossRefGoogle Scholar
  384. 384.
    Carney R, Cotter J, Firth J, Bradshaw T, Yung AR. Cannabis use and symptom severity in individuals at ultra-high risk for psychosis: a meta-analysis. Acta Psychiatr Scand. 2017;136(1):5–15.PubMedPubMedCentralCrossRefGoogle Scholar
  385. 385.
    McHugh MJ, McGorry PD, Yung AR, Lin A, Wood SJ, Hartmann JA, Nelson B. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med. 2017;47(4):616–26.PubMedCrossRefPubMedCentralGoogle Scholar
  386. 386.
    Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, de Haan L, van der Gaag M. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med. 2016;46(4):673–81.PubMedCrossRefPubMedCentralGoogle Scholar
  387. 387.
    Vadhan NP, Corcoran CM, Bedi G, Keilp JG, Haney M. Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res. 2017;257:372–4.PubMedPubMedCentralCrossRefGoogle Scholar
  388. 388.
    Burns J. Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des. 2012;18(32):5093–104.PubMedCrossRefPubMedCentralGoogle Scholar
  389. 389.
    Broussard B, Kelley ME, Wan CR, Cristofaro SL, Crisafio A, Haggard PJ, Myers NL, Reed T, Compton MT. Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res. 2013;148(1-3):93–8.PubMedPubMedCentralCrossRefGoogle Scholar
  390. 390.
    Green A, Tohen M, Hamer R, Strakowski S, Lieberman J, Glick I, Clark W, H.R. Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2-3):125–35.PubMedCrossRefPubMedCentralGoogle Scholar
  391. 391.
    Kvitland LR, Ringen PA, Aminoff SR, Demmo C, Hellvin T, Lagerberg TV, Andreassen OA, Melle I. Duration of untreated illness in first-treatment bipolar I disorder in relation to clinical outcome and cannabis use. Psychiatry Res. 2016;246:762–8.PubMedCrossRefPubMedCentralGoogle Scholar
  392. 392.
    Soyka M, Albus M, Immler B, Kathmann N, Hippius H. Psychopathology in dual diagnosis and non-addicted schizophrenics--are there differences? Eur Arch Psychiatry Clin Neurosci. 2001;251(5):232–8.PubMedCrossRefPubMedCentralGoogle Scholar
  393. 393.
    Seddon JL, Birchwood M, Copello A, Everard L, Jones PB, Fowler D, Amos T, Freemantle N, Sharma V, Marshall M, Singh SP. Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: a report from the UK National EDEN Study. Schizophr Bull. 2016;42(3):619–25.PubMedCrossRefPubMedCentralGoogle Scholar
  394. 394.
    Wobrock T, Falkai P, Schneider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS, Derks EM, Boter H, Rybakowski JK, Libiger J, Dollfus S, Lopez-Ibor JJ, Peuskens J, Hranov LG, Gaebel W, Fleischhacker WW, E.s. group. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013;147(1):132–9.PubMedCrossRefPubMedCentralGoogle Scholar
  395. 395.
    Peralta V, Cuesta M. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand. 1992;85(2):127–30.PubMedCrossRefPubMedCentralGoogle Scholar
  396. 396.
    Bersani G, Orlandi V, Gherardelli S, Pancheri P. Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology. 2002;35(5):289–95.PubMedCrossRefPubMedCentralGoogle Scholar
  397. 397.
    Moller T, Linaker OM. Symptoms and lifetime treatment experiences in psychotic patients with and without substance abuse. Nord J Psychiatry. 2004;58(3):237–42.PubMedCrossRefPubMedCentralGoogle Scholar
  398. 398.
    Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012;38(2):316–30.PubMedCrossRefPubMedCentralGoogle Scholar
  399. 399.
    Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res. 2008;100(1-3):242–51.PubMedCrossRefPubMedCentralGoogle Scholar
  400. 400.
    Helle S, Loberg EM, Gjestad R, Schnakenberg Martin AM, Lysaker PH. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Res. 2017;250:92–8.PubMedCrossRefPubMedCentralGoogle Scholar
  401. 401.
    Waterreus A, Badcock JC, Di Prinzio P, Martin-Iverson M, Morgan VA. The impact of current cannabis use on general cognitive function in people with psychotic illness. Schizophr Res. 2017;190:164–71.PubMedCrossRefPubMedCentralGoogle Scholar
  402. 402.
    Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller A, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23(2):195–201.PubMedCrossRefPubMedCentralGoogle Scholar
  403. 403.
    Gonzalez-Ortega I, Alberich S, Echeburua E, Aizpuru F, Millan E, Vieta E, Matute C, Gonzalez-Pinto A. Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. PLoS One. 2015;10(4):e0123707.PubMedPubMedCentralCrossRefGoogle Scholar
  404. 404.
    Hjorthøj C, Østergaard M, Benros M, Toftdahl N, Erlangsen A, Andersen J, Nordentoft M. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry. 2015;2(9):801–8.PubMedCrossRefPubMedCentralGoogle Scholar
  405. 405.
    McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;(10):CD004837.Google Scholar
  406. 406.
    Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry. 2010;71(3):247–54.CrossRefGoogle Scholar
  407. 407.
    Baker A, Thornton L, Hides L, Dunlop A. Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials. Curr Pharm Des. 2012;18(32):4923–37.PubMedCrossRefPubMedCentralGoogle Scholar
  408. 408.
    Tang SM, Ansarian A, Courtney DB. Clozapine Treatment and Cannabis Use in Adolescents with Psychotic Disorders - A Retrospective Cohort Chart Review. J Can Acad Child Adolesc Psychiatry. 2017;26(1):51–8.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PsychiatryAll India Institute of Medical SciencesRaipurIndia
  2. 2.Department of PsychiatryYale University School of MedicineNew HavenUSA
  3. 3.Abraham Ribicoff Research FacilitiesConnecticut Mental Health CenterNew HavenUSA
  4. 4.Schizophrenia and Neuropharmacology Research GroupVA Connecticut Healthcare SystemWest HavenUSA

Personalised recommendations